Related Experiment Video
Updated: Jun 6, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report
Mumtaz A Niazi1, Ashaur Azhar, Kashif Tufail
1Mumtaz A Niazi, Ashaur Azhar, Kashif Tufail, Eyob L Feyssa, Marlene McGregory, Victor Araya, Jorge A Ortiz, Center for Liver Disease and Transplantation, Albert Einstein Healthcare Network, Philadelphia, PA 19141, United States.
Abstract:
The recommended therapy for chronic hepatitis C (CHC) infection is the combination of a Pegylated interferon and Ribavirin. Almost all such patients on combination therapy experience one or more adverse events during the course of treatment. Significant neurological side effects are rare. A few cases of Bell's Palsy, chronic inflammatory demyelinating polyneuropathy and even one case of acute demyelinating polyneuropathy with atypical features for Guillain-Barre syndrome (GBS) associated with Interferon therapy have been reported but no report of GBS with typical features has been published. We present a case report of typical GBS associated with Peginterferon alfa-2a and Ribavirin used for treatment of CHC infection.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Pancreatitis II: Pathophysiology
Cytomegalovirus Disease
Inhibitors of Viral Protein Synthesis
